Abbott Laboratories 2014 Annual Report Download - page 66

Download and view the complete annual report

Please find page 66 of the 2014 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

FINANCIAL REVIEW
ABBOTT 2014 ANNUAL REPORT
64
A comparison of significant product and product group sales is as
follows. Percent changes are versus the prior year and are based
on unrounded numbers.
(dollars inmillions) 2014
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals
Key Emerging Markets $2,308 1% (7)«% 8%
Other Emerging Markets 810 39÷« (4)÷÷ 43÷«
Nutritionals—
International Pediatric
Nutritionals 2,357 5÷« (2)÷÷ 7÷«
U.S. Pediatric Nutritionals 1,521 (1)÷« —÷÷ (1)÷«
International Adult
Nutritionals 1,761 10÷« (4)÷÷ 14÷«
U.S. Adult Nutritionals 1,314 (3)÷« —÷÷ (3)÷«
Diagnostics—
Immunochemistry 3,614 5÷« (2)÷÷ 7÷«
Vascular Products (1)—
Drug Eluting Stents (DES)
and Bioresorbable Vascular
Scaold (BVS) products 1,463 (6)÷« (1)÷« (5)÷«
Other Coronary Products 580 —÷« (1)÷« 1÷«
Endovascular 527 11÷« (1)÷« 12÷«
(1) Other Coronary Products include primarily guidewires and balloon catheters.
Endovascular includes vessel closure, carotid stents and other peripheral products.
(dollars inmillions) 2013
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals
Key Emerging Markets $2,281 1% (5)«% 6%
Other Emerging Markets 581 13 ÷ (1)÷÷ 14÷«
Nutritionals—
International Pediatric
Nutritionals 2,257 9 ÷ (1) ÷« 10÷«
U.S. Pediatric Nutritionals 1,532 2 ÷ — ÷« 2÷«
International Adult
Nutritionals 1,601 8 ÷ (3) ÷« 11÷«
U.S. Adult Nutritionals 1,350 (3) ÷ — ÷« (3)÷«
Diagnostics—
Immunochemistry 3,458 5 ÷ (3) ÷« 8÷«
Vascular Products (2)—
Drug Eluting Stents (DES)
and Bioresorbable Vascular
Scaold (BVS) products 1,563 (2) ÷ (3) ÷« 1÷«
Other Coronary Products 579 (3) ÷ (1) ÷« (2)÷«
Endovascular 475 5 ÷ — ÷« 5÷«
(2) Other Coronary Products include primarily guidewires and balloon catheters.
Endovascular includes vessel closure, carotid stents and other peripheral products.
RESULTS OF OPERATIONS
SALES
The following table details the components of sales growth by
reportable segment for the last three years:
Total %
Change
Components of % Change
Price Volume Exchange
Total Net Sales
2014 vs. 2013 3.0 (1.4) 6.9 (2.5)
2013 vs. 2012 3.2 (0.6) 5.9 (2.1)
Total U.S.
2014 vs. 2013 (1.4) (3.9) 2.5 —
2013 vs. 2012 (0.5) (0.8) 0.3 —
Total International
2014 vs. 2013 5.0 (0.2) 8.9 (3.7)
2013 vs. 2012 5.0 (0.6) 8.7 (3.1)
Established Pharmaceutical Products Segment
2014 vs. 2013 9.0 2.1 12.8 (5.9)
2013 vs. 2012 3.3 0.8 6.7 (4.2)
Nutritional Products Segment
2014 vs. 2013 3.2 0.8 4.2 (1.8)
2013 vs. 2012 4.3 3.2 2.2 (1.1)
Diagnostic Products Segment
2014 vs. 2013 3.9 (0.9) 7.3 (2.5)
2013 vs. 2012 5.9 (2.5) 10.8 (2.4)
Vascular Products Segment
2014 vs. 2013 (0.9) (6.4) 6.9 (1.4)
2013 vs. 2012 (1.9) (6.2) 6.2 (1.9)
The increases in Total Net Sales in 2014 and 2013 reflect unit
growth, partially oset by the impact of unfavorable foreign
exchange. The price declines related to Vascular Products sales
in 2014 and 2013 primarily reflect pricing pressure on drug
eluting stents and other coronary products as a result of market
competition in the U.S. and other major markets. The impact
of reimbursement reductions by the Centers for Medicare and
Medicaid Services on Abbott’s Diabetes Care business also con-
tributed to the overall 3.9% price decline in the U.S. in 2014.